Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

116.59 +1.29 (+1.12%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
40 41 Next >
2 Top Dividend Stocks You Can Buy and Hold Forever
These two companies have been growing their payouts for more than a century combined. 
Via The Motley Fool
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Why The Apple Watch Comes Up Short In Heart Attack Detection… And Other Alternatives
While there can be some value in having a single-lead ECG always available, patients with known heart conditions need much better technology. 
Via Talk Markets
7 Dividend Kings to Buy for an Uncertain Market Environment
With so much turbulence in the global economy, these dividend kings to buy may help you weather the extreme storm. 
Via InvestorPlace
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
2 Top Dividend Kings to Buy for the Long Haul
These aren't just dividend plays, either. 
Via The Motley Fool
Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories
The FDA will allow two of Abbott's CGMs to be paired with automated insulin pumps. 
Via Investor's Business Daily
Abbott's MitraClip Shows Long Term Benefits In Patients With Leaky Heart Valves
Via Benzinga
Data Shows Abbott's TriClip System Superior To Other Medical Therapy In Heart Valve Disorder
Via Benzinga
2 High-Yield Dividend Stocks to Buy in March
Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years. 
Via The Motley Fool
ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT
From Kahn Swick & Foti, LLC
Via Business Wire
1 High-Flying Growth Stock With 19% Upside, According to Wall Street
This company could keep going up, but beware of the risks. 
Via The Motley Fool
Dexcom Nears Breakout On A Surprise Medicare Decision For Its Devices
The decision came months ahead of Dexcom's and Abbott's expectations. 
Via Investor's Business Daily
Build Your Wealth by Buying and Holding These 2 Dividend Stocks for at Least 20 Years
The road to wealth is long, but it'll be a bit shorter with the right investments. 
Via The Motley Fool
Get a Dividend Every Month With These 3 Healthcare Stocks
With a little planning, you can receive a dependable dividend payout every month. 
Via The Motley Fool
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
Exposures COVID-19 Product Safety Securities Market
Why Abbott Laboratories Stock Bumped Higher Today
The company's specialized heart care products appear to prove their value in clinical testing. 
Via The Motley Fool
How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE:ABT) short percent of float has risen 11.43% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.78% of all regular... 
Via Benzinga
Should Abbott and DexCom Investors Be Worried About Apple's Latest News?
The continuous glucose monitoring market could heat up. 
Via The Motley Fool
Better Dividend Stock: Abbott Laboratories or Medtronic?
One of these top dividend stocks is a far more compelling buy today. 
Via The Motley Fool
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Better Buy: Abbott Laboratories or DexCom Stock?
Both stocks should benefit from the growth in diabetes care. 
Via The Motley Fool
Why Abbott Laboratories Stock Sank Today
The company's glucose monitoring business might come under some serious pressure. 
Via The Motley Fool
What Does Apple Have To Do With DexCom Stock Trading Lower?
DexCom shares (NASDAQ: DXCM) are trading lower on Wednesday following a report that Apple Inc (NASDAQ: AAPL) is making progress on no-prick glucose tracking for its Watch. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Top Dividend Kings to Buy for the Long Haul
These companies have more than 150 years of dividend growth between them. 
Via The Motley Fool
2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands
A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks. 
Via The Motley Fool
Interview With David Rolfe of Wedgewood Partners
Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe. 
Via The Motley Fool
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.